Schedule

How does Δ40p53 alter WTp53 function?

Cecilia Blair LEVANDOWSKI, University of Colorado Boulder, USA

Duration: 25'

The role of Δ40p53 in the response to DNA damaging therapies in breast cancer cells

Kelly AVERY-KIEJDA, University of Newcastle, Australia

Duration: 25'

Functional interplay between p53 and p53/p73 isoforms in human melanoma

Neda SLADE, Ruđer Bošković Institute, Zagreb, Croatia

Duration: 25'

Dissecting the binding landscape and gene regulatory network of p63 and p53

Martin FISCHER, Leibniz Institute on Aging – Fritz Lipmann Institute, Germany

Duration: 15'

Determinants of cis-regulatory activity for the p53 family of transcription factors

Morgan A. SAMMONS, State University of New York at Albany, USA

Duration: 15'

Formation of protein adducts causes inactivation of p53 protein and its aggregation

Alexander ZAIKA, University of Miami Health System, USA

Duration: 25'

∆133p53ß isoform invasive activity: mechanism of action and regulation

Pierre ROUX, CRBM CNRS, France

Duration: 25'

The prognostic impact of p53 aggregates in high-grade serous ovarian cancer

Nicole HEINZL, Medical University of Vienna, Austria

Duration: 15'

p53: dictator of epigenetic vulnerabilities in human glioma

Alea MILLS, Cold Spring Harbor Laboratories, USA

Duration: 25'

p53 controls genomic stability and temporal differentiation of human neural stem cells and affects neural organisation in human brain organoids

Margareta WILHELM, Karolinska Institute, Stockholm, Sweden

Duration: 25'

Roles of p63 during ectoderm specification

Juan J. TENA, Andalusian Center for Development Biology CABD, Seville, Spain

Duration: 25'

p53 isoform delta113p53 promotes zebrafish heart regeneration via maintaining ROS homeostasis

Ting ZHAO, University of Zhejian, China

Duration: 25'

Transcription factor p63: guardian of the epithelial cell fate?

Jo Huiqing ZHOU, Radboud Institute of Molecular Life Sciences, Nijmegen, The Netherlands

Duration: 25'

p73 an architect of epithelial tissue

Maria C. MARIN, Universidad de León, Spain

Duration: 25'

Regulation Of Netrin-1 By p53 Isoforms

Yan SUN, Cancer Research Centre of Lyon, UMR INSERM 1052 – CNRS 5286

Duration: 15'

Mutant p53 Antagonizes p63/p73-Mediated Tumor Suppression via Notch1

Jin ZHANG, University of California, Davis, USA

Duration: 15'

Overlapping transcriptional programs downstream of p63 and p73 promote cutaneous squamous cell carcinoma

Caterina MISSERO, University of Naples Federico II, Naples, Italy

Duration: 25'

p53 status dictates pro-metastatic systemic inflammation in breast cancer

Max WELLENSTEIN, Netherlands Cancer Institute, The Netherlands

Duration: 25'

Δ133p53β isoform regulates unique gene sets involved in immunosuppression, cell growth and cell migration (15)

Marina KAZANTSEVA, University of Otago, Dunedin, New Zealand

Duration: 15'

Targeting Δ133p53α as a novel T cell enhancer factor to improve cellular-based immunotherapy for cancer

Hakim ECHCHANNAOUI, Johannes Gutenberg University Mainz, Germany

Duration: 15'

Modulation of Dendritic Cell function by Δ133p53 isoforms

Sunali MEHTA, University of Otago, Dunedin, New Zealand

Duration: 15'

Role of p53 in the interplay between host cell and pathogens

Thomas MEYER, Max Planck Institute for Infection Biology, Germany

Duration: 25'

An antiviral role for p53 against HIV-1 in macrophages and the implication of the p53 isoforms

Yann BRETON Centre de recherche du CHU de Québec-Université Laval, Canada

Duration: 15'

Opposite effect of p53 on chikungunya virus replication in mammal and insect

Lucie CAPPUCCIO, UMR754, Lyon, France and Institut Pasteur Shanghai, China

Duration: 15'

Identification of novel partners/regulators of p73 proteins in gastric cancer

Anaïs BLANCHET; INSERM UMR_S1113, University of Strasbourg, France

Duration: 15'

Role of the p53 family in muscle atrophy associated with ALS and cancer

Christian GAIDDON, INSERM, University of Strasbourg, France

Duration: 25'

Elevated levels of Δ133p53β isoform are found in Rheumatoid Arthritis patients with hyperproliferative synovium and exaggerated immune cell infiltration

Antony BRAITHWAITE, University of Otago, New Zealand

Duration: 25'

Pan-cancer analysis reveals alternate mechanisms for AKT activation through TAp63 regulated oncogenic lncRNAs (TROLLs)

Elsa FLORES, Moffitt Cancer Center, Tampa, Florida, USA

Duration: 25'

Mechanism of inhibition and activation of TAp63α in oocytes

Volker DÖTSCH, Goethe-University, Frankfurt, Germany

Duration: 25'

Functional analysis of wild-type and mutant p53 isoforms

Sebastien JORUIZ, NCI NIH, USA

Duration: 15'

Germline variant affecting p53β isoforms predisposes to various familial cancers

Tom VAN WEZEL, Leiden University Medical Centre, The Netherlands

Duration: 25'

Impact of p63 upregulation on MAPK inhibitors resistance in melanoma

Daniele BERGAMASCHI, Blizard Institute – Barts and The London, UK

Duration: 25'

Thalidomide teratogenicity uncovered- the central role of p63 and CRBN

Luisa GUERRINI, University of Milano, Italy

Duration: 25'

Impact of p53 isoforms over-expression in lung cancer

Yari CIRIBILLI, CIBIO-Centre for Integrative Biology, University of Trento, Italy

Duration: 25'

Tissue-specific tumor suppressor functions of p53 in vivo

James MANFREDI, Icahn School of Medicine at Mount Sinai, USA

Duration: 25'

DeltaNp73 expression impacts on stem-like cell properties of acute myeloid leukemia and hepatocellular carcinoma tumors

Claude CARON DE FROMENTEL, Cancer Research Center of Lyon, France

Duration: 25'

DNA damage-induced alternative splicing of p53

Michael KASTAN, Duke Cancer Institute, Durham, USA

Duration: 25'

Quantitation and analysis of alternatively-spliced TP53 RNAs in a NZ breast cancer cohort, using a novel multiplex long amplicon digital PCR method

Annette LASHAM, University of Otago, New Zealand

Duration: 25'

Targeting nonsense-mediated decay and mRNA splicing to activate p53 pathway in p53 mutant and non-mutant cancer cells

Jayanthi P. GUDIKOTE, University of Texas M.D. Anderson Cancer Center, Houston, USA

Duration: 15'

The RNA Binding protein PTBP1 controls the alternative splicing of the C-terminal Exons of TP63 in HNSCC

William TAYLOR, Univ Rennes, CNRS, IGDR, UMR 6290, France

Duration: 15'

Targeting the p53-Rbm38 loop for tumor suppression

Xinbin CHEN Comparative Oncology Laboratory, University of California, USA

Duration: 25'

In the loop with p53: isoforms and cancer

Sue HAUPT, Peter MacCallum Cancer Centre, Melbourne, Australia

Duration: 25'

The landscape of p53 isoforms in normal blood cells and acute leukemia

Bjørn GJERTSEN, University of Bergen, Norway

Duration: 25'

Exosomal ΔNp73, TAp73 and Δ133p53 isoforms as early diagnosis markers in colorectal cancer

GEMMA DOMÍNGUEZ, CSIC-UAM, IdiPaz, Madrid, Spain

Duration: 15'

Rescue of missense and nonsense mutant p53: from bench to bedside

Klas WIMAN, Karolinska Institute, Stockholm, Sweden

Duration: 25'

Drug repositioning to target p73 for improved cancer therapy

Joanna ZAWACKA-PANKAU, Stockholm, Sweden

Duration: 25'

Targeting MDM proteins in wt and mutant p53 cancers

Ygal HAUPT, Peter MacCallum Cancer Centre, Melbourne, Australia

Duration: 25'

The E3 ubiquitin-protein ligase Mdm2 is a novel interactor of the von Hippel-Lindau tumor suppressor

Giovanni MINERVINI, University of Padova, Dept. Biomedical Sciences, Italy

Duration: 15'

DAZAP2 acts as phosphorylation-dependent specifier of the p53 response controling cancer cell chemosensitivity

Thomas G HOFMANN, Institute of Toxicology, University of Mainz. Germany

Duration: 15'

P53 family isoforms and mutations in response to microenvironmental stressors

Ivano AMELIO, University of Cambridge, UK

Duration: 25'

Functional genomics identifies a novel p53 induced ligand-independent TRAIL-R2/FLIP complex as a novel therapeutic vulnerability

Simon MCDADE, Queen’s University Belfast, UK

Duration: 25'